HUP0300195A2 - Heterociklusos nátrium/proton-csere inhibitorok és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Heterociklusos nátrium/proton-csere inhibitorok és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0300195A2 HUP0300195A2 HU0300195A HUP0300195A HUP0300195A2 HU P0300195 A2 HUP0300195 A2 HU P0300195A2 HU 0300195 A HU0300195 A HU 0300195A HU P0300195 A HUP0300195 A HU P0300195A HU P0300195 A2 HUP0300195 A2 HU P0300195A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- heteroaryl
- amino
- sulfonyl
- alkynyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 amino- Chemical class 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000006684 polyhaloalkyl group Polymers 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 125000006323 alkenyl amino group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000006319 alkynyl amino group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 239000004004 anti-anginal agent Substances 0.000 abstract 1
- 229940124345 antianginal agent Drugs 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 abstract 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 1
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
A találmány az általános képletű vegyületekre - ahol n 1, 2, 3, 4 vagy5; X nitrogénatom vagy <C-R5 csoport, amelyben R5 hidrogén-,halogénatom, alkenil-, alkinil-, alkoxi-, alkil-, aril- vagyheteroarilcsoport; Z heteroarilcsoport; R1, R2, R3 és R4 egymástólfüggetlenül előnyösen hidrogénatom, alkil-, alkenil-, alkinil-,alkoxi-, alkenil-oxi-, alkinil-oxi-, (alkil- vagy aril)3-szilil-,cikloalkil-, cikloalkenil-, amino-, alkil-amino-, dialkil-amino-,alkenil-amino-, alkinil-amino-, aralkil-amino-, aril-, aralkil-, aril-amino-, aril-oxi-, ciklohetero, alkil-, cikloheteroalkil-alkil-,heteroaril-, heteroaril-amino-, heteroaril-oxi-, aril-tio-, aril-szulfinil-, aril-szulfonil-, merkapto-, alkil-tio-, alkil-szulfinil-,alkil-szulfonil-, heteroaril-tio-, heteroaril-szulfinil-, heteroaril-szulfonil-csoport, halogénatom, halogén-alkil-, polihalogén-alkil-,polihalogén-alkoxi-, amino-tio-, amino-szulfinil-, szulfámoil-,(alkil-szulfonil)-amino- vagy (alkenil-szulfonil)-amino-alkinil-szulfonil)-aminocsoport - és gyógyszerészetileg elfogadható sóikra,sztereoizomereikre és prodrugjaikra vonatkozik. A vegyületeknátrium/proton-csere (NHE) inhibitorok, és így antiangináshatóanyagokként, illetve kardioprotektív hatóanyagokkénthasznosíthatók. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15875599P | 1999-10-12 | 1999-10-12 | |
PCT/US2000/027461 WO2001027107A2 (en) | 1999-10-12 | 2000-10-02 | Heterocyclic sodium/proton exchange inhibitors and method |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300195A2 true HUP0300195A2 (hu) | 2003-07-28 |
HUP0300195A3 HUP0300195A3 (en) | 2003-09-29 |
Family
ID=22569562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300195A HUP0300195A3 (en) | 1999-10-12 | 2000-10-02 | Heterocyclic sodium/proton exchange inhibitors and pharmaceutical compositions containing them |
Country Status (26)
Country | Link |
---|---|
US (2) | US6887870B1 (hu) |
EP (1) | EP1224183B1 (hu) |
JP (1) | JP2003527331A (hu) |
KR (1) | KR20020038818A (hu) |
CN (1) | CN1468232A (hu) |
AR (1) | AR026023A1 (hu) |
AT (1) | ATE314364T1 (hu) |
AU (1) | AU7859600A (hu) |
BR (1) | BR0014725A (hu) |
CA (1) | CA2388813A1 (hu) |
CO (1) | CO5251416A1 (hu) |
DE (1) | DE60025245T2 (hu) |
DK (1) | DK1224183T3 (hu) |
ES (1) | ES2254236T3 (hu) |
HK (1) | HK1045691A1 (hu) |
HU (1) | HUP0300195A3 (hu) |
IL (1) | IL148517A0 (hu) |
MX (1) | MXPA02003626A (hu) |
NO (1) | NO20021717L (hu) |
NZ (1) | NZ517668A (hu) |
PE (1) | PE20011001A1 (hu) |
PL (1) | PL366131A1 (hu) |
RU (1) | RU2002111867A (hu) |
TR (1) | TR200201014T2 (hu) |
WO (1) | WO2001027107A2 (hu) |
ZA (1) | ZA200202479B (hu) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US7217701B2 (en) | 2001-10-11 | 2007-05-15 | Katsuhiko Mikoshiba | Intracellular calcium concentration increase inhibitors |
WO2003045383A1 (en) * | 2001-11-26 | 2003-06-05 | Arachnova Therapeutics Ltd. | Use of ppar activators for the treatment of pulmonary fibrosis |
WO2004022536A1 (en) * | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
KR20050065624A (ko) | 2002-10-23 | 2005-06-29 | 그렌마크 파머수티칼스 엘티디. | 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물 |
EP1565463B1 (en) | 2002-11-18 | 2008-06-11 | Novartis AG | Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases |
SI1599468T1 (sl) * | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije |
JP2006516572A (ja) * | 2003-01-14 | 2006-07-06 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 代謝モジュレーターとしての1,2,3−トリ置換アリール誘導体および1,2,3−トリ置換ヘテロアリール誘導体ならびにこれらの誘導体に関連する糖尿病および高血糖のような障害の予防および処置 |
CA2522023A1 (en) | 2003-04-11 | 2004-10-21 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
EP1862181A3 (en) * | 2003-04-11 | 2010-09-15 | High Point Pharmaceuticals, LLC | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
CN1795181A (zh) * | 2003-05-29 | 2006-06-28 | 麦克公司 | 用作11β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物 |
GB0315950D0 (en) | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
JP4920410B2 (ja) | 2003-07-14 | 2012-04-18 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療 |
ES2326979T3 (es) | 2003-07-24 | 2009-10-22 | Euro-Celtique S.A. | Compuestos de piperidina y composiciones farmaceuticas que contienen a los mismos. |
WO2005047268A2 (en) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
WO2005090282A1 (en) | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
JP2009519206A (ja) | 2004-10-13 | 2009-05-14 | グレンマーク・ファーマシューティカルズ・エスエー | N−(3,5−ジクロロピリジン−4−イル)−4−ジフルオロメトキシ−8−メタンスルホンアミド−ジベンゾ[b,d]フラン−1−カルボキサミドの製造法 |
US7576212B2 (en) | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
EA014956B1 (ru) | 2004-12-17 | 2011-04-29 | ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. | Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений |
US7943634B2 (en) | 2004-12-17 | 2011-05-17 | Glenmark Pharmaceuticals S.A. | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors |
EP1891038B1 (en) | 2005-05-13 | 2008-10-29 | Eli Lilly And Company | Substituted n-arylpyrrolidines as selective androgen receptor modulators |
GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
AU2008246202B2 (en) | 2007-04-27 | 2011-12-01 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
PE20130325A1 (es) | 2007-04-27 | 2013-03-18 | Purdue Pharma Lp | Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1 |
BRPI0812590A2 (pt) | 2007-06-05 | 2015-02-18 | Sanofi Aventis | Derivados de di(hetero) aricicloexano, sua preparação, seu uso e composições farmacêuticas compreendendo-os |
GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
US8703962B2 (en) * | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
LT2384318T (lt) | 2008-12-31 | 2018-02-26 | Ardelyx, Inc. | Junginiai ir būdai, skirti nhe-medijuoto antiporto slopinimui, gydant sutrikimus, susijusius su skysčių kaupimusi ir druskų pertekliumi, bei virškinamojo trakto sutrikimus |
WO2011162409A1 (en) | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
AU2012267491B2 (en) | 2011-06-10 | 2017-07-06 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
UA113288C2 (xx) | 2011-06-22 | 2017-01-10 | Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування | |
US9394293B2 (en) | 2011-08-10 | 2016-07-19 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
US8765959B2 (en) * | 2011-12-23 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Piperidine derivatives |
AR090880A1 (es) * | 2012-04-30 | 2014-12-10 | Janssen R & D Ireland | Derivados de pirimidina |
WO2013178572A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Triazolo compounds as pde10 inhibitors |
WO2014010748A1 (en) * | 2012-07-10 | 2014-01-16 | Shionogi & Co., Ltd. | Cyclopropane derivative having bace1 inhibiting activity |
JP6009851B2 (ja) * | 2012-07-27 | 2016-10-19 | 日本曹達株式会社 | 1h−テトラゾール誘導体の製造方法 |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
EP3988120A1 (en) | 2013-04-12 | 2022-04-27 | Ardelyx, Inc. | Nhe3-binding compounds and methods for inhibiting phosphate transport |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
CN108349891B (zh) | 2015-06-22 | 2022-04-05 | 艾尼纳制药公司 | 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐 |
JP6526352B2 (ja) | 2016-03-22 | 2019-06-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ニコチン性アセチルコリン受容体のアロステリック調節剤 |
JP6948345B2 (ja) * | 2016-04-29 | 2021-10-13 | イオメット ファーマ リミテッド | インドールアミン2,3−ジオキシゲナーゼ及び/又はトリプトファン−2,3−ジオキシゲナーゼの阻害薬としての新規置換イミダゾピリジン化合物 |
KR20190128626A (ko) | 2017-01-09 | 2019-11-18 | 알데릭스, 인코포레이티드 | Nhe-매개 역수송의 저해제 |
JP7292207B2 (ja) | 2017-01-09 | 2023-06-16 | アルデリックス, インコーポレイテッド | 消化管障害を処置するために有用な化合物 |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
WO2018149940A1 (en) | 2017-02-17 | 2018-08-23 | Quimica Sintetica, S. A. | Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process |
WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
WO2018234488A1 (en) | 2017-06-23 | 2018-12-27 | Basf Se | SUBSTITUTED CYCLOPROPYL DERIVATIVES |
KR20200074085A (ko) | 2017-08-04 | 2020-06-24 | 알데릭스, 인코포레이티드 | 고칼륨혈증 치료를 위한 글리시레틴산 유도체 |
WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
CN114008065A (zh) | 2019-02-07 | 2022-02-01 | 阿德利克斯股份有限公司 | 用于治疗高钾血症的甘草次酸衍生物 |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
JP2022548696A (ja) | 2019-09-18 | 2022-11-21 | 武田薬品工業株式会社 | 血漿カリクレインインヒビター及びその使用 |
WO2022086920A1 (en) * | 2020-10-20 | 2022-04-28 | Blacksmith Medicines, Inc. | Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof |
EP4308228A1 (en) * | 2021-03-17 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1206498B (it) | 1983-07-18 | 1989-04-27 | Angeli Inst Spa | Derivati amidinici del4-fenilmidazolo 2-sostituto processi per la loro preparazione e loro uso farmaceutico. |
FR2579596B1 (fr) * | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
IT1201454B (it) * | 1985-08-19 | 1989-02-02 | Boehringer Biochemia Srl | 1,4-diidropiridine-2-sostituite |
US4663473A (en) * | 1986-08-25 | 1987-05-05 | The United States Of America As Represented By The Secretary Of The Army | Isocyanates from oxalyl chloride and amines |
FR2674855B1 (fr) * | 1991-04-03 | 1994-01-14 | Synthelabo | Derives de piperidine, leur preparation et leur application en therapeutique. |
US5380858A (en) * | 1992-04-01 | 1995-01-10 | The University Of Toledo | Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists |
FR2696177B1 (fr) * | 1992-09-28 | 1995-05-12 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
CA2237273C (en) * | 1996-01-15 | 2009-01-13 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
FR2765221B1 (fr) | 1997-06-25 | 1999-07-30 | Synthelabo | Derives de 4-[(1h-imidazol-4-yl)piperidin-1-yl]anilide, leur preparation et leur application en therapeutique |
FR2765580B1 (fr) | 1997-07-01 | 1999-08-06 | Synthelabo | Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique |
FR2772377B1 (fr) * | 1997-12-12 | 2000-01-07 | Synthelabo | Derives de 1-(1-h-imidazol-2-yl)pyrrolidines et 1-(1-h-imidazol-2-ylpiperidines), leur preparation et leur application en therapeutique |
US6011059A (en) * | 1997-12-24 | 2000-01-04 | Bristol-Myers Squibb Company | Acyl guanidine sodium/proton exchange inhibitors and method |
EP1136489A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperidin-1-yl]pyrimidone derivatives |
-
2000
- 2000-09-25 US US09/669,298 patent/US6887870B1/en not_active Expired - Lifetime
- 2000-10-02 DE DE60025245T patent/DE60025245T2/de not_active Expired - Lifetime
- 2000-10-02 PL PL00366131A patent/PL366131A1/xx unknown
- 2000-10-02 ES ES00968723T patent/ES2254236T3/es not_active Expired - Lifetime
- 2000-10-02 BR BR0014725-7A patent/BR0014725A/pt not_active Expired - Fee Related
- 2000-10-02 MX MXPA02003626A patent/MXPA02003626A/es unknown
- 2000-10-02 HU HU0300195A patent/HUP0300195A3/hu unknown
- 2000-10-02 WO PCT/US2000/027461 patent/WO2001027107A2/en active IP Right Grant
- 2000-10-02 TR TR2002/01014T patent/TR200201014T2/xx unknown
- 2000-10-02 AT AT00968723T patent/ATE314364T1/de active
- 2000-10-02 KR KR1020027004653A patent/KR20020038818A/ko not_active Application Discontinuation
- 2000-10-02 DK DK00968723T patent/DK1224183T3/da active
- 2000-10-02 CA CA002388813A patent/CA2388813A1/en not_active Abandoned
- 2000-10-02 CN CNA008140626A patent/CN1468232A/zh active Pending
- 2000-10-02 AU AU78596/00A patent/AU7859600A/en not_active Abandoned
- 2000-10-02 EP EP00968723A patent/EP1224183B1/en not_active Expired - Lifetime
- 2000-10-02 NZ NZ517668A patent/NZ517668A/en unknown
- 2000-10-02 IL IL14851700A patent/IL148517A0/xx unknown
- 2000-10-02 JP JP2001530325A patent/JP2003527331A/ja not_active Withdrawn
- 2000-10-02 RU RU2002111867/04A patent/RU2002111867A/ru not_active Application Discontinuation
- 2000-10-10 CO CO00077054A patent/CO5251416A1/es not_active Application Discontinuation
- 2000-10-10 PE PE2000001081A patent/PE20011001A1/es not_active Application Discontinuation
- 2000-10-12 AR ARP000105372A patent/AR026023A1/es not_active Application Discontinuation
-
2002
- 2002-03-27 ZA ZA200202479A patent/ZA200202479B/xx unknown
- 2002-04-11 NO NO20021717A patent/NO20021717L/no not_active Application Discontinuation
- 2002-09-30 HK HK02107204.5A patent/HK1045691A1/zh unknown
-
2005
- 2005-01-31 US US11/046,993 patent/US7326705B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US7326705B2 (en) | 2008-02-05 |
AU7859600A (en) | 2001-04-23 |
CO5251416A1 (es) | 2003-02-28 |
RU2002111867A (ru) | 2004-05-10 |
EP1224183A2 (en) | 2002-07-24 |
PL366131A1 (en) | 2005-01-24 |
HUP0300195A3 (en) | 2003-09-29 |
TR200201014T2 (tr) | 2003-01-21 |
IL148517A0 (en) | 2002-09-12 |
ZA200202479B (en) | 2004-10-27 |
ES2254236T3 (es) | 2006-06-16 |
NO20021717L (no) | 2002-06-10 |
US6887870B1 (en) | 2005-05-03 |
CN1468232A (zh) | 2004-01-14 |
CA2388813A1 (en) | 2001-04-19 |
ATE314364T1 (de) | 2006-01-15 |
JP2003527331A (ja) | 2003-09-16 |
HK1045691A1 (zh) | 2002-12-06 |
PE20011001A1 (es) | 2001-11-25 |
WO2001027107A3 (en) | 2002-01-24 |
DE60025245T2 (de) | 2006-08-24 |
EP1224183B1 (en) | 2005-12-28 |
NO20021717D0 (no) | 2002-04-11 |
KR20020038818A (ko) | 2002-05-23 |
AR026023A1 (es) | 2002-12-26 |
DK1224183T3 (da) | 2006-03-06 |
WO2001027107A2 (en) | 2001-04-19 |
BR0014725A (pt) | 2003-06-17 |
US20050137216A1 (en) | 2005-06-23 |
DE60025245D1 (de) | 2006-02-02 |
MXPA02003626A (es) | 2003-09-22 |
NZ517668A (en) | 2004-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300195A2 (hu) | Heterociklusos nátrium/proton-csere inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
NL350075I2 (hu) | ||
NO20051389L (no) | Stabilisert farmasoytisk blanding inneholdende basiske hjelpemidler | |
HUP0300350A2 (hu) | Új 3-amino-azetidin-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
DK1106612T3 (da) | Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase | |
DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
YU77503A (sh) | Derivati pirazola za tretiranje hiv | |
BR0308081A (pt) | Inibidores de histona desacetilase | |
DK1070056T3 (da) | Phthalazinon-PDE III/IV-inhibitorer | |
HUP0300867A2 (hu) | Aril-szubsztituált pirazolok, triazolok és tetrazolok és alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP9903916A2 (hu) | Foszfinsavamidok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0300616A2 (hu) | Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
MXPA05009359A (es) | Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. | |
RS101304A (sr) | Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi | |
BR0007589A (pt) | Inibidores da proliferação de células | |
HUP9700005A2 (hu) | 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények | |
MXPA05011176A (es) | Derivados de carboxamida como agentes antidiabeticos. | |
IL136359A (en) | Dihydrobenzofuran substituted phthalazin-1-one derivatives and pharmaceutical compositions containing the same | |
NZ516100A (en) | Streptogramin derivatives, preparation and compositions containing them | |
HUP0300677A2 (hu) | Újfajta indolszármazékok, és azok gyógyszerként történő alkalmazása és eljárás az előállításukra | |
HUP0301706A2 (hu) | Comt gátló hatással rendelkezż kumarinszármazékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
DE60318874D1 (en) | Pyrazolderivate | |
DE69905143D1 (de) | Anti-tumor-mittel | |
HUP0303204A2 (hu) | 1-Metilkarbapenem-származékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP9800817A2 (hu) | Halogén-alk(en)oxi-szubsztituenseket tartalmazó szulfonil-amino-karbonil-triazolinon-származékok, intermedierjeik, előállításuk és alkalmazásuk, hatóanyagként ezeket a vegyületeket tartalmazó herbicid vagy fungicid készítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |